GlaxoSmithKline reported 2.5B in Selling and Administration Expenses for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 2.98B 99M
Alcon AG ALC:SW 776M 7M
Amgen AMGN:US $ 1.31B 79M
AstraZeneca AZN:LN 2.99B 412M
Bayer BAYN:GR 3.77B 19M
Biogen BIIB:US $ 654.1M 16.8M
Bristol Myers Squibb BMY:US $ 1.79B 95M
Eli Lilly And LLY:US $ 1.58B 107.8M
Fresenius FRE:GR 1.3B 100M
Fresenius Medical Care FME:GR 731M 99.18M
Galapagos GLPG:NA 45.45M 15.51M
Genmab GEN:DC 306M 42M
Gilead Sciences GILD:US $ 1.18B 173M
GlaxoSmithKline GSK:LN 2.5B 6M
Glaxosmithkline GSK:US 2.5B 6M
GRIFOLS GRF:SM 249.86M 7.28M
H. Lundbeck A/S LUN:DC 1.59B 15M
Hikma Pharmaceutical HIK:LN 232M 3M
Merck MRK:GR 1.38B 34M
Merk MRK:US $ 2.27B 9M
Novartis NOVN:VX 3.6B 109M
Orion ORNBV:FH 51.2M 8.9M
Pfizer PFE:US $ 2.73B 61M
Philips PHIA:NA 1.2B 11M
Recordati REC:IM 116.24M 1.18M
Regeneron Pharmaceuticals REGN:US $ 445M 30.3M